Stocks scoring 25–45 beat the S&P 500
45.3% of the time over the next three months, since 2015.
How we measured this →
6
hedge funds
hold it · 2 new, 2 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$6.4B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BELITE BIO INC
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including…
Who's behind the signal
Every informed buyer we can see on BLTE, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BELITE BIO INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
2
New positions
2
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to BELITE BIO INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BELITE BIO INC or any security.